e-learning
resources
Vienna 2012
Tuesday, 04.09.2012
Idiopathic pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Predictors of effects and adverse effects of pirfenidone on idiopathic pulmonary fibrosis
T. Arai, Y. Inoue, C. Sugimoto, Y. Sasaki, K. Tachibana, N. Sakamoto, T. Okuma, M. Akira, M. Kitaichi, S. Hyashi (Sakai, Japan)
Source:
Annual Congress 2012 - Idiopathic pulmonary fibrosis
Session:
Idiopathic pulmonary fibrosis
Session type:
Poster Discussion
Number:
3160
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Arai, Y. Inoue, C. Sugimoto, Y. Sasaki, K. Tachibana, N. Sakamoto, T. Okuma, M. Akira, M. Kitaichi, S. Hyashi (Sakai, Japan). Predictors of effects and adverse effects of pirfenidone on idiopathic pulmonary fibrosis. Eur Respir J 2012; 40: Suppl. 56, 3160
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 26 (146) 170057; 10.1183/16000617.0057-2017
Year: 2017
Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019
Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF treatment II
Year: 2016
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis
Source: ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021
Year: 2021
Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis
Source: Eur Respir J, 54 (6) 1901188; 10.1183/13993003.01188-2019
Year: 2019
Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease
Source: Eur Respir J 2004; 24: Suppl. 48, 280s
Year: 2004
Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J, 50 (4) 1701157; 10.1183/13993003.01157-2017
Year: 2017
The potential impact of azithromycin in idiopathic pulmonary fibrosis
Source: Eur Respir J, 53 (2) 1800628; 10.1183/13993003.00628-2018
Year: 2019
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis
Source: Eur Respir J 2016; 47:1776-1784
Year: 2016
Factors affecting the compliance to antifibrotic treatment in patients with interstitial pulmonary fibrosis
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Effects of short-term pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 628s
Year: 2006
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Source: Eur Respir J 2015; 45: 1434-1445
Year: 2015
Treatment efficacy of idiopathic pulmonary fibrosis depending on the dose difference of pirfenidone
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020
Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Effect of baseline statin use on benefit of nintedanib
Source: International Congress 2016 – IPF treatment II
Year: 2016
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
Source: Eur Respir J 2016; 48: 843-851
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept